Goldline Pharmac

Why is Goldline Pharmac falling/rising?

As of 04-Jul, Goldline Pharmaceutical Ltd's stock price is Rs 42.40, up slightly by 0.4%. However, it has experienced negative performance over the past week and month, is close to its 52-week low, and shows a bearish trend with declining investor interest.

As of 04-Jul, Goldline Pharmaceutical Ltd's stock price is currently at Rs 42.40, reflecting a slight increase of Rs 0.17 or 0.4%. Despite this uptick, the stock has shown a negative performance over the past week and month, with declines of 1.97% and 1.30%, respectively. Additionally, the stock is currently 2.66% away from its 52-week low of Rs 41.41, indicating that it is close to a significant low point.<BR><BR>The stock's performance today is characterized by underperformance against its sector, with a decline of 0.77%. Furthermore, the stock has been trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. There has also been a notable decrease in investor participation, with delivery volume dropping by 75.61% compared to the 5-day average, which may indicate reduced interest from investors.<BR><BR>Overall, while there is a minor increase in the stock price today, the broader context shows a trend of falling performance and declining investor engagement, which could contribute to a cautious outlook for Goldline Pharmaceutical Ltd.

Which are the latest news on Goldline Pharmac?

What does Goldline Pharmac do?

Goldline Pharmaceutical Ltd is a Micro Cap company that markets pharmaceutical products. It was incorporated in 2004 and became public in 2013, with a market cap of INR 41 Cr and key metrics including a P/E of 11.00 and a return on equity of 27.33%.

Overview:<BR>Goldline Pharmaceutical Ltd is engaged in the marketing of pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History:<BR>Goldline Pharmaceutical Ltd was originally incorporated on August 2, 2004, as a private limited company under the name 'Goldline Pharmaceutical Private Limited.' It was later converted into a public limited company, with the name changed to 'Goldline Pharmaceutical Limited' effective September 23, 2013. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 41 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 11.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.73<BR>Return on Equity: 27.33%<BR>Price to Book: 4.05<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Goldline Pharmac?

As of 10th June, Goldline Pharmaceutical Ltd has a market capitalization of 41.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 10.35 Cr and Total Assets of 26.28 Cr reported as of March 2025. There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Goldline Pharmaceutical Ltd has a market capitalization of 41.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 10.35 Cr and Total Assets valued at 26.28 Cr.

Who are the peers of the Goldline Pharmac?

Goldline Pharmac's peers include Kabra Drugs, Veerhealth Care, Mangalam Drugs, and others. Kabra Drugs and Roopa Industries show excellent management and growth, while Mangalam Drugs has the lowest 1-year return at -65.43%.

Peers: The peers of Goldline Pharmac are Kabra Drugs, Veerhealth Care, Mangalam Drugs, Vista Pharma., Rajnish Wellness, Sandu Pharma., Murae Organisor, Lasa Supergeneri, Roopa Industries, and ANG Lifesciences.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kabra Drugs and Roopa Industries, while Average management risk is found at Rajnish Wellness. Below Average management risk is noted for Veerhealth Care, Mangalam Drugs, Vista Pharma., Sandu Pharma., Murae Organisor, Lasa Supergeneri, ANG Lifesciences, and the rest. In terms of Growth, Excellent growth is seen at Kabra Drugs and Roopa Industries, Good growth is noted at Murae Organisor, while Average growth is found at Veerhealth Care, and Below Average growth is observed at Mangalam Drugs, Vista Pharma., Rajnish Wellness, Sandu Pharma., Lasa Supergeneri, ANG Lifesciences, and the rest. For Capital Structure, Good capital structure is present at Veerhealth Care and Sandu Pharma., Average capital structure is seen at Lasa Supergeneri, while Below Average capital structure is noted for Kabra Drugs, Mangalam Drugs, Vista Pharma., Rajnish Wellness, Murae Organisor, Roopa Industries, ANG Lifesciences, and the rest.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 86.81%, while Mangalam Drugs has the lowest at -65.43%. Goldline Pharmac's 1-year return is not available for comparison. Additionally, the six-month return is negative for Murae Organisor, Vista Pharma., Rajnish Wellness, Lasa Supergeneri, and ANG Lifesciences.